A commentary in npj Aging argues that chronological age is a poor proxy for physiological status and that biological age measures, interpreted through machine learning, can close the gap between experimental biomarkers and clinical decision-making. The authors position AI as the mechanism that makes multi-biomarker aging clocks usable at the point of care rather than confined to research settings. For longevity practice, this reframes risk stratification around measurable rates of aging rather than years lived.
Key Points
- Chronological age misrepresents physiological status in clinical risk assessment
- AI translates multi-biomarker aging clocks into point-of-care decisions
- Biological age bridges geroscience research and personalized preventive medicine
Longevity Analysis
Accurate measurement precedes effective intervention. Aging clocks built from methylation, proteomic, metabolic, and inflammatory markers capture how circulation, immune defense, hormonal regulation, and tissue repair are actually performing — information that birth date cannot supply. The clinical value depends on interpretation: a composite score that mislabels a transient stress state as accelerated aging produces the wrong intervention, which is why serial measurement over time matters more than any single reading.
Original published by Nature - npj Aging, by Pawel Kordowitzki.